Blocking TAZ activity within tumour cells might thus have a dual beneficial role, by both suppressing intrinsic malignant features of the cancer cells and reversing the immune suppressive TME, thereby potentially also rendering the tumours more vulnerable to immunotherapy. Here, WWTR1 is linked to neoplasm.